al·o·pe·cia

(ăl′ə-pē′shə, -shē-ə)

Complete or partial loss of hair from the head or other parts of the body.

[Latin alōpecia, fox-mange, from Greek alōpekiā, from alōpēx, alōpek-, fox; see wl̥p-ē- in Indo-European roots.]

al′o·pe′cic (-pē′sĭk) adj.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

alopecia

(ˌæləˈpiːʃɪə)

(Medicine) loss of hair, esp on the head; baldness

[C14: from Latin, from Greek alōpekia, originally: mange in foxes, from alōpēx fox]

Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

al•o•pe•ci•a

(ˌæl əˈpi ʃi ə, -si ə)

n.

loss of hair; baldness.

[1350–1400; Middle English < Latin < Greek alōpekía mange in foxes =alōpek-, s. of alṓpēx fox + -ia -ia]

al`o•pe′cic (-ˈpi sɪk) adj.

alopecia

1. a loss of hair, feathers, or wool.
2. baldness. — alopecic, adj.

alopecia

Patchy loss of hair that can be hereditary or caused by disease or stress.

ThesaurusAntonymsRelated WordsSynonymsLegend:

Noun

alopecia - loss of hair (especially on the head) or loss of wool or feathers; in humans it can result from heredity or hormonal imbalance or certain diseases or drugs and treatments (chemotherapy for cancer)

baldness, phalacrosis - the condition of having no hair on the top of the head

alopecia areata - patchy baldness

Translations

Alopezie

alopécie

alopecia

[ˌæləʊˈpiːʃə] N → alopecia f

Collins Spanish Dictionary - Complete and Unabridged 8th Edition 2005 © William Collins Sons & Co. Ltd. 1971, 1988 © HarperCollins Publishers 1992, 1993, 1996, 1997, 2000, 2003, 2005

al·o·pe·ci·a

n. alopecia, pérdida del cabello.

English-Spanish Medical Dictionary © Farlex 2012

alopecia

n alopecia

Mentioned in

References in periodicals archive

Global Alopecia Drugs Market Information, by Alopecia Type Alopecia Areata, Alopecia Totalis, and Alopecia Universalis, by Product Type Tropical, Oral and Others, by end user Hospitals and Clinics, Saloons and Home Care - Forecast till 2022

Alopecia Drugs Market 2019 Global Industry Analysis, Size, Share, Future Predications, Top Players with Huge Upcoming Trends by 2022

AUAT-201 Oral, a Phase 2 randomized, double-blinded, parallel-group, placebo-controlled trial, evaluated the safety, efficacy, and dose response of three doses of ATI-501 on the regrowth of hair in 87 subjects with AA, including Patchy Alopecia, Alopecia Totalis, and Alopecia Universalis.

Aclaris Therapeutics announces results from Phase 2 ATI-501 study

Alopecia areata (AA) is an autoimmune, non-scarring form of alopecia with wide range of clinical presentations from patchy alopecia to complete loss of scalp hair (Alopecia totalis) and or the entire body (alopecia universalis).

DERMOSCOPIC EVALUATION OF THERAPEUTIC RESPONSE IN ALOPECIA AREATA

It can result in complete baldness (Alopecia Totalis) or the total loss of the body's hair (Alopecia Universalis).

Be informed; Alopecia at a glance

The responders in the 8 mg twice-daily dose group were evenly distributed among patients with patchy alopecia areata and the more severe forms, alopecia totalis and alopecia universalis.

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata

About 65% had patchy AA; the remainder had either alopecia totalis or alopecia universalis.

Anthralin shows promise as second-line agent for alopecia

Alopecia areata is a chronic, nonscarring alopecia with variety of patterns of patchy hair loss, diffuse alopecia, alopecia totalis and universalis, ophiasis.

Trichoscopic features in diagnosis of alopecia areata and its relation to severity of alopecia tool (SALT) score

ALOPECIA AREATA is a challenging condition on many levels, particularly more severe forms such as alopecia totalis or universalis.

How to get through the tough talks about alopecia areata with children

Edinburgh-born Gail developed alopecia totalis in 2005 and lost all her hair.

A Gail force for good; TO BALDLY GO.. SCOTS STAR IS ON A MISSION TO HELP OTHERS It's Alopecia Awareness Month and Gail Porter talks to MARIA CROCE about living with hair loss and the other challenges she's faced

Aclaris is developing ATT50001 as a treatment for patients with alopecia areata (AA), including the more severe forms of AA that result in total scalp hair loss, known as alopecia totalis, and total hair loss on the scalp and body, known as alopecia universalis.

Novartis gains Rydapt approval for AML: BioMarin's Brineura wins FDA approval for Batten disease

The United States Food and Drug Administration has approved the 30-day review period for US-based Aclaris Therapeutics' investigational new drug application for ATI-50001, an orally administered investigational Janus Kinase inhibitor, intended for the potential treatment of alopecia totalis and alopecia universalis, it was reported on Thursdau.

US FDA clears 30-day review period for Aclaris Therapeutics' investigational new drug application for ATI-50001